{"id":"W2514283099","doi":"10.1177/1756287216663073","title":"Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience","year":2016,"lang":"en","type":"review","venue":"Therapeutic Advances in Urology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"FP7 Science in Society; Bristol-Myers Squibb","keywords":"Cabozantinib; Medicine; Sunitinib; Axitinib; Oncology; Metastasis; Renal cell carcinoma; Internal medicine; Targeted therapy; Tyrosine-kinase inhibitor; Cancer research; Vascular endothelial growth factor; Angiogenesis; Tyrosine kinase; Everolimus; Receptor tyrosine kinase; Cancer; Receptor; VEGF receptors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006574139,0.0005713558,0.002860299,0.0002529728,0.00003300176,0.00000607585,0.0003560336,0.0003827511,0.00003794991],"category_scores_gemma":[0.0001007577,0.0002853615,0.0004287281,0.0003248299,0.000742997,0.000113963,0.00004852572,0.0003825316,0.00001083149],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001652343,"about_ca_system_score_gemma":0.0003298231,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001600401,"about_ca_topic_score_gemma":0.00003068755,"domain_scores_codex":[0.995375,0.001311099,0.001645037,0.0008686667,0.0002937442,0.000506442],"domain_scores_gemma":[0.9941221,0.004137425,0.0006844988,0.0009244129,0.00004074284,0.00009085664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009715544,0.001029297,0.001319527,0.000970978,0.00003966147,0.0003014224,0.0007479601,0.000001007543,0.00000401222,0.00005679089,7.839026e-7,0.985813],"study_design_scores_gemma":[0.03503783,0.02070385,0.001444098,0.002150229,0.0009198544,0.0002863952,0.0001345659,0.000003357504,0.00002668324,0.0001947845,0.9387624,0.0003360058],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.06689772,0.9290515,0.00001781348,0.00008856726,0.000384812,0.003164373,0.00000936115,0.00001075174,0.0003750798],"genre_scores_gemma":[0.1218733,0.8766938,0.0001728253,0.00009384812,0.0002175483,0.0008134014,0.00000914208,0.00003626669,0.00008993592],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.985477,"threshold_uncertainty_score":0.9999598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1681734959571597,"score_gpt":0.4580039289744441,"score_spread":0.2898304330172844,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}